Non-viral gene therapies placed precisely where they’re needed.
Location: Canada, Quebec, Montreal
Total raised: $224.08M
Investors 2
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
| - | Forbion | forbion.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.02.2024 | - | $200M | - |
| 26.01.2015 | - | $10.83M | - |
| 02.08.2013 | - | $13.25M | - |
Mentions in press and media 11
| Date | Title | Description |
| 21.05.2024 | Forbion leads $65 million Series A Financing of Progentos Therapeutics | • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs • Progentos Therapeutics is developing novel small molecules to induce de-novo remyelin... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 Apri... |
| 20.02.2024 | enGene Secures $200 Million in Private Placement Financing | enGene Holdings Inc. (Nasdaq: ENGN) successfully closes a $200 million private placement financing, paving the way for continued development of its genetic medicine therapeutic candidate, EG-70. enGene Holdings Inc., a genetic medicines com... |
| 14.02.2024 | enGene Announces Oversubscribed $200 Million Private Placement Financing | Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage geneti... |
| 14.02.2024 | enGene Announces Oversubscribed $200 Million Private Placement Financing | BOSTON and MONTREAL, Feb. 14, 2024 /CNW/ – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle... |
| 16.07.2018 | enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President | MONTRÉAL and BOSTON, /CNW/ – enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs, including the Gene Pill™ , today announced the appointment of Jaso... |
| 26.01.2015 | enGene raises CAD 13.5 million (US$11.5M) to develop intestinal gene delivery platform | enGene Inc., a Montréal-based biotechnology enterprise developing an innovative platform technology for delivering genes to cells lining the gastrointestinal tract, announced today the closing of a $13.5 million Series B investment round le... |
| 02.08.2013 | enGene Raises $13.25M Financing | enGene Inc., a Montreal, Quebec, Canada-based pre-clinical stage biopharmaceutical company developing a platform technology for the delivery of nucleotides (DNA or RNA) to the gut, has held an initial closing of a $13.25m financing. The rou... |
Show more